Compare · BMY vs TAK
BMY vs TAK
Side-by-side comparison of Bristol-Myers Squibb Company (BMY) and Takeda Pharmaceutical Company Limited (TAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMY and TAK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- BMY is the larger of the two at $125.63B, about 2.1x TAK ($58.74B).
- Over the past year, BMY is up 44.9% and TAK is up 28.6% - BMY leads by 16.3 points.
- BMY has been more active in the news (8 items in the past 4 weeks vs 6 for TAK).
- BMY has more recent analyst coverage (25 ratings vs 6 for TAK).
- Company
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Price
- $62.89+2.25%
- $18.86+1.43%
- Market cap
- $125.63B
- $58.74B
- 1M return
- -6.94%
- +3.34%
- 1Y return
- +44.87%
- +28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 6
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Latest BMY
- Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
- Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
- Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
- Bristol Myers Squibb Announces Dividend
- EVP,Chief Med Offr,Head of Dev Massacesi Cristian sold $403,498 worth of shares (6,249 units at $64.57), decreasing direct ownership by 25% to 18,748 units (SEC Form 4)
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
- EVP, Corporate Affairs Short Bartie Wendy exercised 1,236 shares at a strike of $66.92 and covered exercise/tax liability with 633 shares, increasing direct ownership by 5% to 12,684 units (SEC Form 4)
- Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
- SVP and Controller Holzer Phil M sold $33,750 worth of shares (500 units at $67.50), decreasing direct ownership by 3% to 16,862 units (SEC Form 4)
Latest TAK
- Chief Transformation Officer Duprey Lauren Rusckowski sold $640,279 worth of American Depositary Shares (34,535 units at $18.54), decreasing direct ownership by 15% to 191,522 units (SEC Form 4)
- SEC Form 6-K filed by Takeda Pharmaceutical Company Limited
- U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
- New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
- President, R&D Plump Andrew Stewart sold $2,148,372 worth of American Depositary Shares (116,191 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 6-K filed by Takeda Pharmaceutical Company Limited
- Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
- ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- President, R&D Plump Andrew Stewart sold $363,347 worth of American Depositary Shares (19,651 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Human Resources Officer Greenway Nicola Deidre Petal sold $235,118 worth of American Depositary Shares (12,980 units at $18.11), decreasing direct ownership by 24% to 40,049 units (SEC Form 4)